Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: dennis michael patterson who wrote (1819)	2/22/1999 2:21:00 PM
From: David Howe	Read Replies (2) \| Respond to of 10280

Poor Maris, continues to sulk over the fact that he dropped SEPR off of his buy list right before the big Prozac deal was signed. He's the last person you'd want to listen to regarding SEPR. Dave

To: dennis michael patterson who wrote (1819)	2/25/1999 8:46:00 AM
From: wolfdog2	Read Replies (3) \| Respond to of 10280

Dennis, I was just checking through the posts to see if anyone had posted the link to the Forbes' article. Glad to see that you did. I notice that with the exception of one post, the article has been ignored by the board. This board has become a cheerleading section for SEPR. There's a lot to cheer about, but imo not at current prices. As the Forbes' article notes, the earnings (several years out) are not a slam dunk affair. SEPR has half a billion dollars in debt and burns through cash like a drunk through booze. I also question the recent enthusiasm for the small retail investor jumping into the stock. This crowd can jump out just as quickly. Just take a look at a chart of AMZN. In fact I dare say that SEPR (the stock, not the company) is the Amazon.com of the biotech world.